| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Pediatrics, University of Leuven (F.d.Z.), 3000 Leuven, Belgium; Department of Pediatrics, University of Göteborg (K.A.-W.), 41685 Göteborg, Sweden; Department of Pediatrics, University of Tübingen (H.A.W.), 72070 Tübingen, Germany; Department of Pediatrics, University of Lyon (P.C.), 69322 Lyon, France; and Department of Pediatrics, University of Paris (J.-L.C.), 75014 Paris, France; Pharmacia, Inc. (A.L.), 11287 Stockholm, Sweden; Karolinska Institute (B.J.), 17176 Stockholm, Sweden; and Department of Pediatrics, Oregon Health Sciences University (R.G.R.), Portland, Oregon 97201
Address all correspondence and requests for reprints to: Francis de Zegher, M.D., Ph.D., Department of Pediatrics, University Hospital Gasthuisberg, 3000 Leuven, Belgium. E-mail: francis.dezegher{at}uz.kuleuven.ac.be
We report an epi-analysis of 6-yr growth responses obtained with GH treatment in short children born small for gestational age (SGA). Four randomized, multicenter studies explored the effects of continuous and discontinuous regimens of GH treatment in short, non-GH-deficient SGA children. A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively. At the start of the study, the age of these 188 children averaged 5.2 yr (range, 2–8 yr), height was -3.4 SD score, and height adjusted for parental height was -2.4 SD score. Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys.
Two studies essentially investigated the effects of continuous GH treatment at a dose of 33 or 67 µg/kg·day, and two studies focused on the growth characteristics during an initial GH treatment for 2–3 yr (dose range, 33–100 µg/kg·day), followed by a withdrawal phase of 1–2 yr, and then by either no or 1 or more episodes of further GH treatment (33 or 67 µg/kg·day).
Continuous GH treatment for 6 yr resulted in height increments of 2.0 ± 0.2 SD (33 µg/kg·day; n = 35) and 2.7 ± 0.2 SD (67 µg/kg·day; n = 27). Discontinuous GH treatment was given to 77 children, most of them experiencing only 1 (n = 47) or 2 (n = 26) treatment phases with an average duration of 2.0 yr. All these children received GH during the first 2 yr; the dose was only 32 µg/kg·day when averaged over 6 yr. Some individualization of treatment schedules was allowed, and the majority of investigators seemed to aim for a low normal height level, adjusted for parental height. After 2 yr, the mean adjusted height SD score had increased to -0.4 ± 0.1 and stabilized thereafter.
Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age. Multivariate analysis identified the average GH dose over 6 yr, parental-adjusted height SD score, and age at start as prime predictors of the growth response. GH treatment was well tolerated.
In conclusion, this epi-analysis of growth responses over 6 yr confirms the administration of GH as an effective approach to normalize the stature of short, non-GH-deficient SGA children, at least during childhood and early puberty. In addition, it is now increasingly apparent that a relatively broad spectrum of GH regimens is effective, and this experience should facilitate the design of more individualized treatment schedules in the future, in particular for young children.
This article has been cited by other articles:
 |
|
 |
|
  A. Maiorana and S. Cianfarani Impact of Growth Hormone Therapy on Adult Height of Children Born Small for Gestational Age Pediatrics, September 1, 2009; 124(3): e519 - e531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jung, C. Land, C. Nicolay, J. De Schepper, W. F Blum, and E. Schonau Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study Eur. J. Endocrinol., February 1, 2009; 160(2): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. J. de Ridder, T. Stijnen, and A. C. S. Hokken-Koelega Prediction Model for Adult Height of Small for Gestational Age Children at the Start of Growth Hormone Treatment J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. N. Bannink, J. van Doorn, P. G. H. Mulder, and A. C. S. Hokken-Koelega Free/Dissociable Insulin-Like Growth Factor (IGF)-I, Not Total IGF-I, Correlates with Growth Response during Growth Hormone Treatment in Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2992 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Argente, R. Gracia, L. Ibanez, A. Oliver, E. Borrajo, A. Vela, J. P. Lopez-Siguero, M. L. Moreno, F. Rodriguez-Hierro, and on behalf of the Spanish SGA Working Group Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3095 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rosilio, J.-C. Carel, E. Ecosse, J.-L. Chaussainon, and on behalf of the 0908 Lilly Study Group Adult height of prepubertal short children born small for gestational age treated with GH Eur. J. Endocrinol., June 1, 2005; 152(6): 835 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bridges New indications for growth hormone Arch. Dis. Child. Ed. Pract., June 1, 2005; 90(1): ep7 - ep9. [Full Text] [PDF]
|
|
|
|
|
|
F. de Zegher and A. Hokken-Koelega Growth Hormone Therapy for Children Born Small for Gestational Age: Height Gain Is Less Dose Dependent Over the Long Term Than Over the Short Term Pediatrics, April 1, 2005; 115(4): e458 - e462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Brodsky and H. Christou Current Concepts in Intrauterine Growth Restriction J Intensive Care Med, November 1, 2004; 19(6): 307 - 319. [Abstract] [PDF]
|
|
|
|
|
|
Y. K. van Pareren, H. J. Duivenvoorden, F. S. M. Slijper, H. M. Koot, and A. C. S. Hokken-Koelega Intelligence and Psychosocial Functioning during Long-Term Growth Hormone Therapy in Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5295 - 5302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fjellestad-Paulsen, D. Simon, and P. Czernichow Short Children Born Small for Gestational Age and Treated with Growth Hormone for Three Years Have an Important Catch-Down Five Years after Discontinuation of Treatment J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1234 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Boonstra, Y. van Pareren, P. Mulder, and A. Hokken-Koelega Puberty in Growth Hormone-Treated Children Born Small for Gestational Age (SGA) J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5753 - 5758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Massa, C. Heinrichs, S. Verlinde, M. Thomas, J. P. Bourguignon, M. Craen, I. Francois, M. Du Caju, M. Maes, and J. De Schepper Late or Delayed Induced or Spontaneous Puberty in Girls with Turner Syndrome Treated with Growth Hormone Does Not Affect Final Height J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4168 - 4174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Van Pareren, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3584 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lee, J. W. Kendig, and J. R. Kerrigan Persistent Short Stature, Other Potential Outcomes, and the Effect of Growth Hormone Treatment in Children Who Are Born Small for Gestational Age Pediatrics, July 1, 2003; 112(1): 150 - 162. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lee, S. D. Chernausek, A. C. S. Hokken-Koelega, and P. Czernichow International Small for Gestational Age Advisory Board Consensus Development Conference Statement: Management of Short Children Born Small for Gestational Age, April 24-October 1, 2001 Pediatrics, June 1, 2003; 111(6): 1253 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Carel, P. Chatelain, P. Rochiccioli, and J.-L. Chaussain Improvement in Adult Height after Growth Hormone Treatment in Adolescents with Short Stature Born Small for Gestational Age: Results of a Randomized Controlled Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1587 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Ranke, A. Lindberg, C. T. Cowell, K. A. Wikland, E. O. Reiter, P. Wilton, and D. A. Price Prediction of Response to Growth Hormone Treatment in Short Children Born Small for Gestational Age: Analysis of Data from KIGS (Pharmacia International Growth Database) J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 125 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. van Pareren, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Effect of Discontinuation of Growth Hormone Treatment on Risk Factors for Cardiovascular Disease in Adolescents Born Small for Gestational Age J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Kamp, J J J Waelkens, S M P F de Muinck Keizer-Schrama, H A Delemarre-Van de Waal, L Verhoeven-Wind, A H Zwinderman, J M Wit, and P E Clayton High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature Arch. Dis. Child., September 1, 2002; 87(3): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lampit and Z.'e. Hochberg Prevention of Growth Deceleration after Withdrawal of Growth Hormone Therapy in Idiopathic Short Stature J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3573 - 3577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Reiter, S. L. Blethen, J. Baptista, and L. Price Early Initiation of Growth Hormone Treatment Allows Age-Appropriate Estrogen Use in Turner's Syndrome J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1936 - 1941. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
